Hassman Research Institute, LLC.

Berlin, New Jersey 08009

0 studies enrolling now · 15 studies all time

What they study most

Acute Mania, Adverse Effect of Drugs and Medicaments in Therapeutic Use, Bipolar I Disorder, Borderline Personality Disorder, Depressive Disorder, Major, Hot Flashes, Major Depressive Disorder, Migraine, With or Without Aura, Negative Symptoms of Schizophrenia, Opioid Use Disorder, Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

Studies at this site

• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults — Completed
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause — Completed
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 — Completed
• Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers — Completed
• A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder — Completed
• Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia — Completed
• Open Label Safety Study in Acute Treatment of Migraine — Completed
• Safety and Efficacy Study in Adult Subjects With Acute Migraines — Completed
• Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence — Completed
• A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder — Completed
• A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) — Completed